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Rates of Antimicrobial Resistance in Latin America (2004-2007) and in vitro Activity of the
Glycylcycline Tigecycline and of Other Antibiotics
Flávia Rossi1, Patricia García2, Bernardo Ronzon3, Daniel Curcio4, Michael J Dowzicky5
1Hospital das Clínicas da Faculdade de Medicina, University of São Paulo, LIM03, Rua Lee de Forest 32, São Paulo, São Paulo, Brazil;
2Laboratorio de Microbiología, Departamento de Laboratorios Clínicos, Escuela de Medicina. Pontificia Universidad Católica de Chile;
3Hospital Angeles del Pedregal, Camino a Santa Tersa 10 55, col. Heroes de Padierna, Mexico, D.F., Mexico; 4Sanatorio San José,
Infectología Institucional SRL; Buenos Aires, Argentina; 5Wyeth Pharmaceuticals; Collegeville PA, USA
As a part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), Gram-positive and Gram-negative
bacterial isolates were collected from 33 centers in Latin America (centers in Argentina, Brazil, Chile, Colombia,
Guatemala, Honduras, Jamaica, Mexico, Panama, Puerto Rico, and Venezuela) from January 2004 to September
2007. Argentina and Mexico were the greatest contributors of isolates to this study. Susceptibilities were determined
according to Clinical Laboratory Standards Institute guidelines. Resistance levels were high for most key organisms
across Latin America: 48.3% of Staphylococcus aureus isolates were methicillin-resistant while 21.4% of
Acinetobacter spp. isolates were imipenem-resistant. Extended-spectrum β-lactamase were reported in 36.7% of
Klebsiella pneumoniae and 20.8% of E. coli isolates. Tigecycline was the most active agent against Gram-positive
isolates. Tigecycline was also highly active against all Gram-negative organisms, with the exception of Pseuodomonas
aeruginosa, against which piperacillin-tazobactam was the most active agent tested (79.3% of isolates susceptible).
The in vitro activity of tigecycline against both Gram-positive and Gram-negative isolates indicates that it may be
an useful tool for the treatment of nosocomial infections, even those caused by organisms that are resistant to
other antibacterial agents.
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Increased resistance to antibacterial agents among
clinically-important organisms has been widely reported in
recent years [1]. In many cases, these organisms are resistant
to multiple antibacterial agents [2], dramatically limiting
available treatment options. High levels of antibacterial
resistance among many key organisms have been reported in
Latin America, particularly non-fermentative Gram-negative
bacilli (including Acinetobacter spp. and Pseudomonas
aeruginosa) and extended-spectrum β-lactamase (ESBL)-
producing Enterobacteriaceae, but also among some Gram-
positive organisms (including Staphylococcus aureus) [3].
Treatment of infections caused by these organisms is often
complicated because of resistance to first-line antibacterial
agents [4]. Surveillance studies are thus an essential
component in the selection of appropriate empirical therapy,
allowing for the monitoring of antibacterial resistance [5].
Tigecycline is the first commercially available member of a
novel group of antibacterial agents, the glycylcyclines. The
Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) is a
global surveillance study designed to compare the in vitro
activity of tigecycline with a panel of antibacterial agents used
in daily clinical practice against a range of clinically important
organisms. We report on four-year T.E.S.T. data (2004-2007)
for Gram-positive and Gram-negative organisms collected from
Latin America.
Material and Methods
Isolate Collection
For the T.E.S.T. study, Latin America is defined as
including the following countries: Argentina, Brazil, Chile,
Colombia, Guatemala, Honduras, Jamaica, Mexico, Panama,
Puerto Rico and Venezuela (Table 1). Thirty-three Latin
American centers participated in the T.E.S.T. study from
January 2004 to September 2007 (Table 1). Data for 2007 are as
yet incomplete.
Isolates that were determined by local criteria to be
clinically significant were collected from in- and out-patients
with documented nosocomial or community-acquired
infections. Acceptable isolate sources included blood, the
respiratory tract, urine (not exceeding 25% of isolates), skin,
wounds and fluids. Only one isolate per patient was accepted
in the study. Each center was required to contribute the
following: 25 isolates each of Staphylococcus aureus,
Klebsiella spp., Escherichia coli and Enterobacter spp.; 20
isolates of Pseudomonas aeruginosa; 15 isolates each of
Enterococcus spp. and Acinetobacter spp.; and 10 isolates
of Serratia marcescens. A maximum of 200 isolates was
contributed by each center, after local determination of identity
and antibacterial susceptibility.
Antimicrobial Susceptibility Testing
Minimum inhibitory concentrations (MICs) were
determined locally using broth microdilution methodology,
as defined by the Clinical Laboratory Standards Institute (CLSI,
formerly NCCLS) [6], using either MicroScan® panels (Dade
Behring Inc., CA, USA) or Sensititre® plates (TREK Diagnostic
Systems, West Sussex, England). The test panel for Gram-
negative isolates included (concentrations given in μg/mL):
amikacin (0.5-64); amoxicillin-clavulanic acid (0.12/0.06-32/16);
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ampicillin (0.5-32); cefepime (0.5-32); ceftriaxone (0.06-64);
ceftazidime (8-32); imipenem (0.06-16, MicroScan® only);
levofloxacin (0.008-8); minocycline (0.5-16); tigecycline (0.008-
16); and piperacillin-tazobactam (0.06/4-128/4). Gram-positive
organisms were tested against the following agents (in μg/mL):
amoxicillin-clavulanic acid (0.03/0.0015-8/4), ampicillin (0.06-16),
penicillin (0.06-8), linezolid (0.5-8), ceftriaxone (0.03-64), imipenem
(0.12-16, MicroScan® only), levofloxacin (0.06-32), minocycline
(0.25-8), tigecycline (0.008-16), piperacillin-tazobactam (0.25/4-
16/4), and vancomycin (0.12-32). For tigecycline, interpretive
criteria from the US Food and Drug Administration packaging
insert were applied for S. aureus (susceptible ≤0.5 μg/mL),
vancomycin-susceptible E. faecalis (susceptible ≤0.25 μg/mL)
and the Enterobacteriaceae (susceptible ≤2 μg/mL,
intermediate 4 μg/mL, resistant ≥8 μg/mL) [7]. For all other
agents, CLSI interpretive criteria were applied [8].
MIC determinations were carried out using cation-adjusted
Mueller-Hinton broth. Broth microdilution panels inoculated
with Gram-negative organisms were incubated in ambient air
at 35°C for 16-20 hours. Staphylococcus aureus and
Enterococcus spp. were incubated in ambient air at 35°C for
20-24 hours. Quality control testing was carried out on each
day of susceptibility testing, using the following ATCC strains:
E. coli ATCC 25922 and 35218, S. aureus ATCC 29213, P.
aeruginosa ATCC 27853, and E. faecalis ATCC 29212, when
appropriate.
All isolates were sent to a single laboratory, International
Health Management Associates, Inc. (IHMA, Schaumburg,
IL, US), where confirmation of identification was carried out
as well as inclusion of all data into a centralized database.
MIC information was also returned to the central laboratory
for inclusion in this centralized database using an OptiScan
Data Collection Form, part of a proprietary optical character
recognition system. MICs of approximately 10% of isolates
from all centers were checked by IHMA as a part of standard
quality control testing.
Antibacterial Resistance Determination
Confirmation of methicillin resistance was carried out by
IHMA using the cefoxitin disk diffusion method, using 30 μg
disks obtained from Remel, Lenexa, KS, USA.
The presence of ESBLs among K. pneumoniae and E. coli
was detected according to CLSI methodology [8], for which
cefotaxime (30 μg), cefotaxime-clavulanic acid (30/10 μg),
ceftazidime (30 μg) and ceftazidime-clavulanic acid (30/10 μg)
discs were used. An increase of ≥5 mm in inhibition zone on
the combination disc compared to the cephalosporin only
disc suggested an ESBL producing organism.
Results
The incidence of organisms, both resistant and
susceptible, varied widely between species and between
countries during the four-year study period. Most isolates
came from Argentina or Mexico during this study interval
(Tables 2 and 3).
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Gram-Positive Isolates
Staphylococcus aureus
All 905 S. aureus isolates collected between 2004 and 2007
were susceptible to tigecycline, linezolid and vancomycin
(MICs90 0.25, 2 and 1 μg/mL, respectively), while 98.9% were
susceptible to minocycline (MIC90 1 μg/mL) (Table 4). Only
55.7% of isolates were susceptible to levofloxacin. Almost
one-half of these S. aureus isolates (48.3%) were methicillin-
resistant (MRSA) (Table 3).
Enterobacter faecalis and E. faecium
All E. faecalis isolates were susceptible to ampicillin, while
most isolates were susceptible to penicillin (99.2%), linezolid
(97.2%) and vancomycin (96.4%). Low MICs90 were reported
for tigecycline and amoxicillin-clavulanic acid (0.25 and 1 μg/
mL, respectively; Table 4).
Against E. faecium the lowest MICs were reported for
tigecycline (0.12 μg/mL), while 92.5% of isolates were
susceptible to linezolid (MIC90 2 μg/mL). Only 17.0% of isolates
were susceptible to levofloxacin (MIC90 ≥64 μg/mL, Table 4).
Nearly half (44.3%) of the E. faecium isolates observed in this
study were vancomycin resistant (Table 3).
Gram-Negative Isolates
Non-Fermenters
Against the Acinetobacter spp. the lowest MICs90 were
reported for tigecycline and minocycline (2 μg/mL), with 94.9%
of isolates susceptible to minocycline. Only 62.6% of isolates
were susceptible to imipenem (MIC90 ≥32 μg/mL, Table 4).
Few agents were active against P. aeruginosa. Piperacillin-
tazobactam was the most active agent reported against P.
aeruginosa in this study, with 79.3% of isolates susceptible
over the four study years (MIC90 128 μg/mL, Table 4).
Enterobacteriaceae
Imipenem and tigecycline were the most active agents
against Enterobacter spp., with 99.2 and 96.2% of isolates
susceptible, respectively. Susceptibility to cephalosporins
ranged from 58.0% to ceftazidime to 80.9% to cefepime
(Table 4).
High susceptibilities were reported among isolates of K.
pneumoniae against imipenem (99.6%; MIC90 1 μg/mL) and
tigecycline (95.7%; MIC90 2 μg/mL) (Table 4).
Tigecycline was the most active agent against E. coli; all
isolates were susceptible (MIC90 0.5 μg/mL). Other active
agents included imipenem (99.7% susceptible), amikacin
(97.3% susceptible) and piperacillin-tazobactam (91.0%
susceptible) (Table 4).
Among isolates of S. marcescens, 99.5% were susceptible to
imipenem, while 97.3% were susceptible to tigecycline (Table 4).
Resistant Isolates
Tigecycline, vancomycin, linezolid and minocycline were
effective against MRSA, with MICs90 of 0.25, 1, 2 and 4 μg/
mL, respectively. Susceptibilities to these agents were also
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Table 4. In vitro activity of tigecycline and other antibiotics against Gram-positive and Gram-negative organisms collected in
Latin America from 2004-2007.
Overall (2004-2007)
Antibacterial N MIC50 MIC90 %S* %R* MIC range
Gram positives
S. aureus
Tigecycline 905 0.12 0.25 100 N/A 0.03 - 0.5
Penicillin 905 ≥16 ≥16 6.5 93.5 ≤0.06 - ≥16
Ampicillin 905 16 ≥32 8.4 91.6 ≤0.06 - ≥32
Amoxicillin-clavulanic acid 905 2 ≥16 57.7 42.3 0.06 - ≥16
Piperacillin-tazobactam 905 2 ≥32 59.4 40.6 ≤0.25 - ≥32
Ceftriaxone 905 4 ≥128 54.7 39.4 0.12 - ≥128
Imipenem† 538 0.25 ≥32 59.5 36.8 ≤0.12 - ≥32
Levofloxacin 905 0.25 16 55.7 41.2 ≤0.06 -≥64
Minocycline 905 ≤0.25 1 98.9 0.2 ≤0.25 -≥16
Linezolid 905 2 2 100 N/A ≤0.5 - 4
Vancomycin 905 1 1 100 0.0 ≤0.12 - 2
E. faecalis
Tigecycline 393 0.12 0.25 N/A N/A ≤0.008 - 1
Penicillin 393 2 4 99.2 0.8 ≤0.06 - ≥16
Ampicillin 393 1 2 100 0.0 ≤0.06 - 8
Amoxicillin-clavulanic acid 393 0.5 1 N/A N/A 0.06 - 8
Piperacillin-tazobactam 393 2 8 N/A N/A ≤0.25 - ≥32
Imipenem† 229 1 8 N/A N/A ≤0.12 - ≥32
Levofloxacin 393 1 32 71.0 27.7 0.25 - ≥64
Minocycline 393 8 ≥16 38.7 24.4 ≤0.25 - ≥16
Linezolid 393 2 2 97.2 0.0 ≤0.5 - 4
Vancomycin 393 1 2 96.4 2.8 ≤0.12 - ≥64
E. faecium
Tigecycline 106 0.06 0.12 100 0.0 ≤0.008 - 0.25
Penicillin 106 ≥16 ≥16 22.6 77.4 ≤0.06 - ≥16
Ampicillin 106 ≥32 ≥32 25.5 74.5 0.12 - ≥32
Amoxicillin-clavulanic acid 106 ≥16 ≥16 N/A N/A 0.12 - ≥16
Piperacillin-tazobactam 106 ≥32 ≥32 N/A N/A ≤0.25 - ≥32
Ceftriaxone 106 ≥128 ≥128 N/A N/A 0.12 - ≥128
Imipenem† 54 ≥32 ≥32 N/A N/A 0.5 - ≥32
Levofloxacin 106 ≥64 ≥64 17.0 78.3 0.5 -≥64
Minocycline 106 1 ≥16 61.3 22.6 ≤0.25 - ≥16
Linezolid 106 2 2 92.5 0.0 ≤0.5 - 4
Vancomycin 106 2 ≥64 53.8 44.3 ≤0.12 - ≥64
Gram negatives
Acinetobacter spp.
Tigecycline 486 0.5 2 N/A N/A ≤0.008 - 8
Tigecycline 486 0.5 2 96.7 0.4 ≤0.008 - 8
(Enterobacteriaceae breakpoints¥)
Ampicillin 486 ≥64 ≥64 N/A N/A ≤0.5 - ≥64
Amoxicillin-clavulanic acid 486 ≥64 ≥64 N/A N/A ≤0.12 - ≥64
Piperacillin-tazobactam 486 128 ≥256 19.1 62.3 ≤0.06 - ≥256
Ceftazidime 486 ≥64 ≥64 18.1 75.1 ≤8 - ≥64
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Ceftriaxone 486 ≥128 ≥128 8.4 79.4 ≤0.06 - ≥128
Cefepime 486 32 ≥64 25.9 54.1 ≤0.5 -≥64
Imipenem† 313 1 ≥32 62.6 33.2 0.12 - ≥32
Levofloxacin 486 8 ≥16 19.5 62.1 ≤0.008 - ≥16
Amikacin 486 32 ≥128 35.6 46.1 ≤0.5 - ≥128
Minocycline 486 ≤0.5 2 94.9 2.1 ≤0.5 - ≥32
P. aeruginosa
Tigecycline 715 8 ≥32 N/A N/A 0.12 - ≥32
Ampicillin 715 ≥64 ≥64 N/A N/A 1- ≥64
Piperacillin-tazobactam 715 8 128 79.3 20.7 ≤0.06 - ≥256
Ceftazidime 715 ≤8 ≥64 60.0 30.5 ≤8 - ≥64
Cefepime 715 8 ≥64 61.5 22.8 ≤0.5 - ≥64
Imipenem† 446 1 16 66.1 18.8 0.12 - ≥32
Levofloxacin 715 2 ≥16 50.5 45.0 0.03 - ≥16
Amikacin 715 4 64 72.2 18.5 ≤0.5 - ≥128
Minocycline 715 ≥32 ≥32 5.2 79.6 ≤0.5 - ≥32
Enterobacter spp.
Tigecycline 766 0.5 2 96.2 0.3 0.06 - 8
Ampicillin 766 ≥64 ≥64 0.4 93.5 4 - ≥64
Amoxicillin-clavulanic acid 766 ≥64 ≥64 3.3 94.6 1 - ≥64
Piperacillin-tazobactam 766 4 128 68.4 15.5 0.12 - ≥256
Ceftazidime 766 ≤8 ≥64 58.0 36.2 ≤8 - ≥64
Ceftriaxone 766 1 ≥128 61.6 28.5 ≤0.06 -≥128
Cefepime 766 ≤0.5 ≥64 80.9 14.5 ≤0.5 - ≥64
Imipenem† 484 0.5 1 99.2 0.6 ≤0.06 - ≥32
Levofloxacin 766 0.06 ≥16 76.6 19.6 ≤0.008 - ≥16
Amikacin 766 2 32 89.4 5.4 ≤0.5 - ≥128
Minocycline 766 4 ≥32 72.5 17.6 ≤0.5 - ≥32
K. pneumoniae
Tigecycline 763 0.5 2 95.7 1.3 0.12 - 8
Ampicillin 763 ≥64 ≥64 0.3 90.4 1 - ≥64
Amoxicillin-clavulanic acid 763 16 ≥64 49.1 35.0 0.5 - ≥64
Piperacillin-tazobactam 763 4 ≥256 66.1 22.9 0.12 - ≥256
Ceftazidime 763 ≤8 ≥64 56.7 35.3 ≤8 - ≥64
Ceftriaxone 763 1 ≥128 56.7 35.6 ≤0.06 - ≥128
Cefepime 763 1 ≥64 67.6 26.5 ≤0.5 -≥64
Imipenem† 459 0.5 1 99.6 0.4 ≤0.06 - ≥32
Levofloxacin 763 0.25 ≥16 63.4 32.2 ≤0.008 -≥16
Amikacin 763 2 32 88.3 7.5 ≤0.5 - ≥128
Minocycline 763 2 16 72.6 18.1 ≤0.5 - ≥32
E. coli
Tigecycline 932 0.25 0.5 100 0.0 ≤0.008 - 2
Ampicillin 932 ≥64 ≥64 25.6 73.3 ≤0.5 - ≥64
Amoxicillin-clavulanic acid 932 8 32 56.0 20.0 ≤0.12 - ≥64
Piperacillin-tazobactam 932 1 16 91.0 4.1 ≤0.06 - ≥256
Ceftazidime 932 ≤8 32 77.9 12.4 ≤8 - ≥64
Ceftriaxone 932 ≤0.06 ≥128 71.0 23.9 ≤0.06 - ≥128
Cefepime 932 ≤0.5 32 80.4 14.6 ≤0.5 - ≥64
Imipenem† 583 0.25 0.5 99.7 0.2 ≤0.06 - ≥32
Levofloxacin 932 0.5 ≥16 53.8 41.2 ≤0.008 - ≥16
Amikacin 932 2 8 97.3 1.3 ≤0.5 - ≥128
Minocycline 932 2 16 68.3 18.7 ≤0.5 - ≥32
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Table 5. In vitro activity of tigecycline and other antibiotics against resistant Gram-positive and Gram-negative organisms
collected in Latin America from 2004-2007.
S. marcescens
Tigecycline 328 1 2 97.3 0.6 0.12 - 8
Ampicillin 328 ≥64 ≥64 0.3 94.5 4 -≥64
Amoxicillin-clavulanic acid 328 ≥64 ≥64 2.4 93.3 2 - ≥64
Piperacillin-tazobactam 328 2 128 80.2 11.0 ≤0.06 - ≥256
Ceftazidime 328 ≤8 32 79.0 12.5 ≤8 - ≥64
Ceftriaxone 328 0.5 ≥128 73.5 20.4 ≤0.06 -≥128
Cefepime 328 ≤0.5 ≥64 81.7 14.6 ≤0.5 - ≥64
Imipenem† 220 0.5 1 99.5 0.0 ≤0.06 - 8
Levofloxacin 328 0.12 4 84.5 9.8 ≤0.008 - ≥16
Amikacin 328 4 32 79.9 9.8 ≤0.5 - ≥128
Minocycline 328 2 8 85.7 5.8 ≤0.5 - ≥32
*Susceptibility and resistance were only determined when ≥10 isolates were available; †Imipenem numbers are lower due to some
isolates being tested with meropenem (data not shown); ¥using Enterobacteriaceae breakpoints (S = 2, R = 8 μg/mL); N/A indicates
breakpoint was not available.
Antibacterial N MIC50 MIC90 %S* %R MIC range
Gram-positives
MRSA
Tigecycline 437 0.12 0.25 100 N/A 0.03 - 0.5
Levofloxacin 437 8 32 12.8 83.1 ≤0.06 - ≥64
Minocycline 437 ≤0.25 4 98.4 0.2 ≤0.25 -≥16
Linezolid 437 2 2 100 N/A ≤0.5 - 4
Vancomycin 437 1 1 100 0.0 0.25 - 2
VR E. faecium¦
Tigecycline 47 0.06 0.12 N/A N/A 0.03 - 0.25
Penicillin 47 ≥16 ≥16 4.3 95.7 4 - ≥16
Ampicillin 47 ≥32 ≥32 4.3 95.7 2 - ≥32
Piperacillin-tazobactam 47 ≥32 ≥32 N/A N/A 16 - ≥32
Imipenem§ 22 ≥32 ≥32 N/A N/A 8 - ≥32
Levofloxacin 47 ≥64 ≥64 0.0 100 16 - ≥64
Minocycline 47 ≤0.25 ≥16 74.5 17.0 ≤0.25 - ≥16
Linezolid 47 2 2 97.9 0.0 1 - 4
Vancomycin 47 ≥64 ≥64 0.0 100 32 - ≥64
Gram-negatives
Imipenem-R Acinetobacter
Tigecycline 104 0.5 2 N/A N/A 0.12 - 8
Tigecycline 104 0.5 2 97.1 1.0 0.12 - 8
(Enterobacteriaceae breakpoint¥)
Ampicillin 104 ≥64 ≥64 N/A N/A 32 - ≥64
Amoxicillin-clavulanic acid 104 ≥64 ≥64 N/A N/A 16 -≥64
Piperacillin-tazobactam 104 ≥256 ≥256 1.9 95.2 4 - ≥256
Ceftazidime 104 ≥64 ≥64 6.7 89.4 ≤8 - ≥64
Ceftriaxone 104 ≥128 ≥128 0.0 92.3 16 - ≥128
Cefepime 104 ≥64 ≥64 3.8 83.7 4 - ≥64
Imipenem§ 104 ≥32 ≥32 0.0 100 16 - ≥32
Levofloxacin 104 8 ≥16 4.8 68.3 0.25 -≥16
Amikacin 104 64 ≥128 13.5 74.0 2 - ≥128
Minocycline 104 ≤0.5 2 98.1 1.0 ≤0.5 - 16
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ESBL+ K. pneumoniae
Tigecycline 280 0.5 2 93.6 1.8 0.12 - 8
Ampicillin 280 ≥64 ≥64 0.0 98.9 16 - ≥64
Amoxicillin-clavulanic acid 280 32 ≥64 12.9 61.8 2 - ≥64
Piperacillin-tazobactam 280 64 ≥256 35.0 42.9 0.25 - ≥256
Imipenem§ 185 0.5 1 99.5 0.5 ≤0.06 - 16
Levofloxacin 280 8 ≥16 33.6 58.9 ≤0.008 - ≥16
Amikacin 280 8 ≥128 76.8 14.3 ≤0.5 - ≥128
Minocycline 280 4 ≥32 65.7 21.4 ≤0.5 - ≥32
ESBL+ E. coli
Tigecycline 194 0.25 0.5 100 0.0 0.06 - 2
Ampicillin 194 ≥64 ≥64 0.0 99.5 16 - ≥64
Amoxicillin-clavulanic acid 194 16 32 22.7 30.9 2 - ≥64
Piperacillin-tazobactam 194 8 32 86.1 3.6 0.25 - ≥256
Imipenem§ 110 0.25 0.5 99.1 0.0 ≤0.06 - 8
Levofloxacin 194 ≥16 ≥16 9.8 84.5 0.015 - ≥16
Amikacin 194 4 16 94.3 3.1 ≤0.5 - ≥128
Minocycline 194 4 ≥32 61.3 25.8 ≤0.5 - ≥32
*Susceptibility was only determined when ≥10 isolates were available; §Imipenem numbers are lower due to some isolates being tested
with meropenem; ¦VR E. faecalis are not reported here as only four were reported during the four study years (2 in 2005, 2 in 2006);
¥using Enterobacteriaceae breakpoints (S = 2, R = 8 μg/mL); N/A indicates breakpoint is not available.
high (100% for tigecycline, vancomycin and linezolid and
98.4% for minocycline) (Table 5).
Tigecycline was the most active agent against vancomycin-
resistant (VR) E. faecium, with a MIC90 of 0.12 μg/mL over the
four study years (Table 5). Linezolid was also active against
VR E. faecium, with a MIC90 of 2 μg/mL and 97.9% of isolates
susceptible (Table 5).
Imipenem-resistant Acinetobacter spp. had reduced
susceptibility to most agents, with the exceptions of tigecycline
(MIC90 2 μg/mL) and minocycline (MIC90 2 μg/mL) (Table 5).
Tigecycline and imipenem were the most active agents
against ESBL-positive K. pneumoniae, with 93.6 and 99.5%
of isolates susceptible, respectively (MIC90s of 2 and 1 μg/
mL, respectively). Similarly, tigecycline and imipenem were
the most active agents against ESBL-positive E. coli, with
susceptibilities of 100 and 99.1%, respectively, and MIC90s of
0.5 μg/mL for each (Table 5).
Discussion
Several global surveillance studies are currently underway,
including the SENTRY and SMART (Study for Monitoring
Antimicrobial Resistance Trends) studies. These and other
surveillance studies allow for the monitoring of global trends
in resistance, as well as providing data on regional resistance
and demographic trends. The T.E.S.T. study has been ongoing
since 2004, collating global and local data on resistance trends
among Gram-positive and Gram-negative organisms from
nosocomial patients and community/outpatients. To date, 384
centers in 48 countries have contributed isolates to the T.E.S.T.
global study.
Among the 33 centers contributing isolates in our study,
19 were located in Argentina and Mexico (11 and 8,
respectively). Despite the fact that Brazil has the largest
population of any country in Latin America, only two centers
from Brazil provided isolates to this study. Thus, results for
Latin America as a whole (44.3% vancomycin resistance among
E. faecium) are biased towards results from those countries
contributing the most isolates, in this case Argentina and
Mexico. The WHONET Program [10,11] has previously shown
high rates of vancomycin resistance among E. faecium isolates
in Argentina (25%-33%) and Chile (41%-58.6%) from 2003 to
2004. The regional collection bias in this study therefore does
not appear to exaggerate the prevalence of vancomycin-
resistant E. faecium in Latin America.
The MRSA accounted for 48.3% of S. aureus isolates
collected across Latin America during our study. This is a
sizeable increase compared to previous studies, which report
MRSA prevalences ranging from 26.5% to 38.6% (during the
1999-2000 winter season [9], from 1997-2001 [12], from 2000-
2001 [13] or among clinical isolates in 2003 [14]). This disparity
may be due in part to differences in countries contributing
isolates to these studies: in Gales et al. [13], 11 centers in six
countries contributed isolates (Argentina, Brazil, Chile,
Colombia, Mexico and Venezuela); in Sader et al. [14], 10 centers
in five undefined countries took part; and Mendes et al. [9]
utilized isolates from 13 centers of three countries (Argentina,
Brazil and Mexico). The study of Mendes et al. [9] focused on
community-acquired respiratory tract organisms, which may
account in part for the difference in susceptibility rates noted
between that study and our current report.
MRSA rates varied widely between countries in this study,
ranging from 16.0% in Jamaica to 77.3% in Puerto Rico. Similar
results have previously been reported by Sader et al. [3], who
found oxacillin resistance rates to vary significantly, even
Rates of Antimicrobial Resistance in Latin America
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between hospitals in the same country. Although MRSA are
typically cross-resistant to several classes of antibacterial
agents, all S. aureus isolates identified in our study were
susceptible to tigecycline.
The results in our study suggest that susceptibility among
isolates of E. coli has decreased in Latin American in recent
years. Sader et al. [12] examined susceptibility rates among
457 E. coli isolates from nosocomial and community-acquired
infections in Latin America from 1997-2001. Of the eight
antibacterial agents used in both studies, susceptibility rates
were lower for six in our study; susceptibility was reduced by
as much as 39.8% in the case of ampicillin. Imipenem
susceptibility was identical in these two studies, while
levofloxacin susceptibility was 3.2% higher in our study.
Previous surveillance studies have shown reduced
susceptibility rates in Latin America to commonly-used
antibacterial agents. Gales et al. [15] reported that isolates of
P. aeruginosa and Acinetobacter spp. from Latin America
have reduced susceptibility rates to most antibacterial agents
compared to isolates from other regions. These conclusions
are supported by our study. Stelling et al. [16] examined
susceptibility trends among E. coli isolates from 10 countries
and found that isolation from Latin America was associated
with increased nonsusceptibility for all six antimicrobial agents
(cefepime, ceftazidime, ciprofloxacin, gentamicin, piperacillin-
tazobactam and tobramycin).
As a result of the high frequencies of ESBLs reported in
the SMART study from 2003-2004, Rossi et al. [17] have
questioned the use of extended-spectrum cephalosporins as
empirical therapy for intra-abdominal infections in some
geographic areas. ESBL-positive E. coli have increased from
12.0% in the Rossi et al. study [17] to 20.8% in our study,
while ESBL-positive K. pneumoniae increased from 27.6% to
36.7%. These increases in ESBL rates over such a short period
reiterate Rossi’s concerns about the use of inappropriate
empirical therapy in the treatment of infections caused by
resistant organisms, especially given that appropriate empirical
therapy has been directly linked to clinical success (i.e., 18).
Tigecycline has been shown here to be highly active
against most organisms collected from Latin America, such as
S. aureus (including MRSA), E. faecalis, E. faecium (including
VR isolates), Acinetobacter spp. (including MDR isolates),
Enterobacter spp., K. pneumoniae (including ESBL-positive
isolates), E. coli (including ESBL-positive isolates) and S.
marcescens. Isolates of S. aureus (including oxacillin-resistant
isolates) and Enterococcus spp. collected in Latin America
from 2000 to 2002 have previously been shown to be highly
susceptible to tigecycline, with MICs90 of 0.5 μg/mL and 100%
susceptibilities reported for both types of bacteria [19].
Tigecycline has previously been shown to be highly active
against these same organisms on a global scale. Hoban et
al. [20], in an early T.E.S.T. study report, presented data on
6,792 clinical isolates collected from 40 centers across
Europe, North America and Asia in 2004. In this study,
tigecycline was shown to be highly active against both
Gram-positive isolates (including E. faecalis, E. faecium
and S. aureus) and Gram-negative isolates (including
Acinetobacter baumannii, Enterobacter aerogenes,
Enterobacter cloacae, E. coli and K. pneumoniae), with
susceptibilities ranging from 91.3% among ESBL-positive
K. pneumoniae isolates to 100% among E. coli (ESBL-
positive and -negative), VR E. faecium and VR E. faecalis
isolates. As in our study, tigecycline had little activity
against P. aeruginosa.
Bacterial resistance to many commonly-used antibacterial
agents is increasing. This is particularly true in Latin America,
where local antibacterial usage patterns and/or dissemination
of resistant clones have led to increased resistance rates [4].
The resistance scenario in Latin America is further complicated
by the recent appearance of metallo-β-lactamases among
isolates of A. baumannii, P. aeruginosa and K. pneumoniae
[21]. The development of new antibacterial agents that work
through novel mechanisms, and are thus not affected by
existing mechanisms of resistance, is critically needed.
Tigecycline is one such agent that has been shown to be
effective against most of the organisms identified in our study,
even those resistant to other agents. Tigecycline may thus
become an important tool in the treatment of infections caused
by Gram-positive and Gram-negative organisms, including
resistant strains.
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